Editor's Note: This version of the Fierce Biotech Fundraising Tracker covering July 19, 2022, through the end of the year has been retired. See the new 2023 version here. 2021 was a banner year for ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
PDS Biotech's Phase 2 study shows potential breakthrough in treating HPV16-positive head and neck cancer. The study shows a 87.1% 12-month survival rate for ICI naive patients, nearly doubling typical ...
AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results